The Hidden Bet Against AI Hardware: Healthcare and Banks Quietly Undervalued
While semiconductor stocks were grabbing headlines with a jaw-dropping 111% surge between late March and late June of 2026, a different story was quietly unfolding in two overlooked corners of the market. Healthcare and financial stocks — both trading at steep discounts to the S&P 500 — may represent the most compelling long-term value hiding in plain sight. For patient investors, the rotation now underway in AI hardware could be the signal worth acting on.
Richard Reyle, chief investment officer at Questar Capital Partners, which oversees $1.3 billion in assets, issued a pointed warning this week: mean reversion is coming for AI chip stocks. The iShares Semiconductor ETF has already fallen 18% from its June 22 peak, yet remains up 70% for 2026. Reyle draws a sobering analogy to the mid-2000s housing bubble, noting that it wasn’t a collapse in home prices that triggered the crisis — it was merely a deceleration in the rate of price increases. “It’s always the second derivative,” he told Business Insider. The same dynamic, he argues, now threatens memory makers and data center chip stocks. Warning signs are already blinking: Meta has begun selling excess compute capacity to other firms, a potential early indicator that AI infrastructure demand is topping out. Add cheaper AI models entering the market and the threat to chip earnings becomes harder to dismiss.
The flip side of this rotation is where long-term value investors should focus their attention. The healthcare sector currently trades at a forward price-to-earnings ratio of 17.9 — a meaningful 12% discount to the S&P 500’s 20.3x multiple. Reyle is particularly bullish on pharmaceutical stocks, citing Eli Lilly specifically as having roughly 25% upside potential driven by surging global demand for GLP-1 drugs like Mounjaro and Zepbound. Healthcare also carries a historically defensive profile, holding up better when broader economic momentum softens. Meanwhile, the financial sector — anchored by major banks posting record quarterly earnings — trades at an even steeper discount of 15.6x forward earnings. JPMorgan’s aggressive nationwide expansion of wealth management branches and Morgan Stanley’s record $148 billion in new assets during Q2 2026 underscore that the earnings engine in financials is accelerating, not fading.
For long-term investors, the lesson here is durable and familiar: the loudest trades are rarely the cheapest ones. When AI hardware commands 70%-plus gains in a single year, the asymmetric opportunity almost always lies elsewhere — in the sectors left behind. Healthcare’s defensive moat, GLP-1 tailwinds, and below-market valuation combine to offer genuine compounding potential over a multi-year horizon. Banks’ wealth management buildout, record earnings, and low P/E multiples tell a similar story. Neither sector requires a market collapse to deliver solid returns — they simply need the market’s attention to drift back toward fundamentals, which, historically, it always does. The compounders that are overlooked today have a way of becoming the winners that everyone wishes they had owned.
